GRAIL (GRAL) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GRAIL (GRAL) has outperformed Veracyte (VCYT) over the past year, gaining 82.2% versus a gain of 24.2%. GRAIL is the larger company by market cap ($5.92 billion vs $3.51 billion), about 1.7 times the size. Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus -277.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRAL | VCYT |
|---|---|---|
| Share price | $132.61 | $43.60 |
| Market cap | $5.92B | $3.51B |
| 1-day change | -0.22% | +1.02% |
| YTD return | +54.94% | +3.56% |
| 1-year return | +82.18% | +24.22% |
| 5-year return | — | -3.45% |
| P/E ratio (TTM) | — | 31.14 |
| Forward P/E | — | 22.36 |
| EPS (TTM) | $-9.70 | $1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $147.17M | $517.14M |
| Revenue growth (YoY) | +17.18% | +16.01% |
| Net income (latest FY) | $-408.35M | $66.35M |
| Gross margin | — | 70.10% |
| Operating margin | -381.98% | 11.17% |
| Net margin | -277.47% | 12.83% |
| 52-week high | $166.48 | $60.91 |
| 52-week low | $41.50 | $29.46 |
| Distance from 52-week high | -20.34% | -28.42% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -15.24% | +33.99% |
| Average volume | 940.82K | 1.36M |
| Shares outstanding | 44.67M | 80.39M |
| Employees | 910 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRAL has outperformed VCYT by 58.0 percentage points over the past year.
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -277.5 cents for GRAIL.
About GRAIL
GRAL stock →GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Health Care · Medical Specialities · 910 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
GRAL vs VCYT FAQ
Which is bigger, GRAIL or Veracyte?
GRAIL (GRAL) is larger, with a market capitalization of $5.92B compared with $3.51B for Veracyte (VCYT).
Which stock has performed better over the past year, GRAL or VCYT?
GRAL returned +82.18% over the past 12 months, compared with +24.22% for VCYT (price return, excluding dividends). Past performance does not predict future results.
Are GRAIL and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.